Newamsterdam pharma announces pricing of upsized $416.5 million public offering of ordinary shares and pre-funded warrants

Naarden, the netherlands and miami, dec. 11, 2024 (globe newswire) -- newamsterdam pharma company n.v. (nasdaq: nams; “newamsterdam” or the “company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“cvd”) with elevated low-density lipoprotein cholesterol (“ldl-c”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the pricing of the previously announced underwritten public offering of (i) 12,117,347 of the company's ordinary shares, nominal value €0.12 per share (the “ordinary shares”), at a public offering price of $24.50 per share and (ii) to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase 4,882,653 ordinary shares at a public offering price of $24.4999 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.0001 per share exercise price for each such pre-funded warrant (“pre-funded warrants,” such offering, the “offering”). the proceeds to the company from the offering, before deducting underwriting discounts and commissions and offering expenses payable by the company, are expected to be approximately $416.5 million. in addition, the company has granted the underwriters a 30-day option to purchase up to an additional 2,550,000 ordinary shares at the public offering price, less underwriting discounts and commissions. the offering is expected to close on or about december 13, 2024, subject to satisfaction of customary closing conditions.
NAMS Ratings Summary
NAMS Quant Ranking